Merrion Pharmaceuticals announced it had secured a further US patent for its lead product to treat bone metastases associated with prostate, breast and other cancers.
The US patent covers Orazol tablets, an oral form of zoledronic acid, that use Merrion’s proprietary gastro-intestinal permeation enhancement technology technology to allow the oral dosing of drugs previously only available in intravenous form. The expiry date for the patent is 2027.
Products developed with this technology may have potential for improving quality of life for patients.
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/irishtimes/VR3765MFOBH2NMV2QNICYDF67M.png)